Association of grade ≥3 neutropenia (NP) with outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel
Year: 2018
Type: article
Abstract: Background: Subset analysis of trials investigating taxanes in patients with mCRPC suggest an association between Grade ≥3NP and disease outcomes. In the Phase 3 PROSELICA trial (NCT01308580), NP was more common in patients receiving cabazitaxel 25mg/m2 (C25) vs cabazitaxel 20mg/m2 (C20) - 73% vs 42%, respectively. Post hoc analyses of PROSELICA examined the relationship between incidence of NP, survival and response.
Source: Annals of Oncology
Authors: A. Meisel, R. de Wit, S. Oudard, O. Sartor, F. Stenner-Liewen, Z. Shun, A. Ozatilgan, M. Eisenberger, J.S. de Bono
Institutions: University of Zurich, ETH Zurich, University Hospital Zurich, Institute of Pharmaceutical Sciences, Erasmus MC, Hôpital Européen Georges-Pompidou, Université Paris Descartes, Tulane Medical Center, University Hospital of Basel, Sanofi (United States), Johns Hopkins University, Johns Hopkins Hospital, Sidney Kimmel Comprehensive Cancer Center, Royal Marsden NHS Foundation Trust, Institute of Cancer Research
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,080
OpenAlex ID: W2898517006